SNGX
SOLIGENIX, INC.Company Information
- Company Name
- SOLIGENIX, INC.
- CIK
- CIK0000812796
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SNGX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SNGX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-10-02
- Last sale
- —
- Shares purchased (TTM)
- 15,132
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 875,696
- Shares outstanding
- 15,951,949
- Ownership
- 5.49%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- -2.56%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 10 | 6 | 8 | 11 | 5 | 7 | 8 | 10 | 9 | 7 | 8 | 10 | ||||||
| Unbilled Receivables Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Grants Receivable Current | - | - | - | - | - | - | - | - | - | 0 | - | 0 | ||||||
| Receivables Long Term Contracts Or Programs | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Deferred Costs Current | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Prepaid Expense Current | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | ||||||
| Assets Current | 10 | 7 | 9 | 11 | 5 | 8 | 9 | 10 | 10 | 8 | 10 | 11 | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Costs | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 10 | 7 | 9 | 11 | 6 | 8 | 9 | 10 | 10 | 8 | 10 | 11 | ||||||
Liabilities Current | ||||||||||||||||||
| Capitalized Contract Cost Net Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 3 | 2 | 2 | ||||||
| Employee Related Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Debt Current | - | - | - | - | - | - | 1 | 2 | 3 | 3 | 2 | 2 | ||||||
| Liabilities Current | 4 | 4 | 4 | 3 | 4 | - | 5 | 5 | 6 | 7 | 6 | 6 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | 0 | 0 | - | 0 | ||||||
| Long Term Debt | - | - | - | - | - | - | 0 | - | - | - | 1 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 256 | 251 | 250 | 250 | 241 | 241 | 238 | 237 | 233 | 228 | 228 | 228 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -250 | -248 | -245 | -242 | -240 | -237 | -234 | -231 | -229 | -228 | -226 | -224 | ||||||
| Stockholders Equity | 7 | 3 | 5 | 8 | 2 | 4 | 4 | 6 | 3 | 1 | 3 | 4 | ||||||
| Liabilities And Stockholders Equity | 10 | 7 | 9 | 11 | 6 | 8 | 9 | 10 | 10 | 8 | 10 | 11 | ||||||
| Series D Preferred Stock | - | - | - | - | - | - | - | - | 0 | - | 0 | 0 | ||||||
| Preferred Stock Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Shares Authorized | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | ||||||
| Debt Instrument Unamortized Discount Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Shares Issued | 22 | 11 | 10 | 10 | 4 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 22 | 11 | 10 | 10 | 4 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSOLIGENIX, INC. (SNGX) — SEC Financial Statements & Analysis
SOLIGENIX, INC. (SNGX) is a pharmaceutical preparations company, incorporated in DE. SOLIGENIX, INC. trades on Nasdaq as: SNGX. SOLIGENIX, INC. (SNGX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, SOLIGENIX, INC. carries a market cap of $6.38M, a P/E ratio of -0.62x, a P/B ratio of 0.96x, a P/S ratio of 35.98x, an enterprise value of $-3.43M, and an EV/EBITDA multiple of 0.31x. On profitability, it posts a gross margin of 52.84%, an operating margin of -9523.35%, a net margin of -8678.82%, a Return on Equity (ROE) of -241.65%, and a Return on Assets (ROA) of -125.95%. Per share, it reports EPS of $-0.64, diluted EPS of $-0.64, free cash flow per share of $-0.61, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -1.16% year-over-year, and EPS growth of -79.69% year-over-year. On the balance sheet, it maintains a current ratio of 2.77x, a quick ratio of 2.67x, working capital of $6.50M, a debt-to-equity ratio of 0.58x, a debt ratio of 0.37, an interest coverage ratio of -46.13x, free cash flow of $-9.75M (TTM), and net debt of $-9.81M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.38M
- P/E TTM
- -0.62x
- EPS TTM
- $-0.64
- P/B TTM
- 0.96x
- ROE TTM
- -241.65%
- ROA TTM
- -125.95%
- Debt To Equity
- 0.58x
- Free Cash Flow TTM
- $-9.75M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is SOLIGENIX, INC. in?
SOLIGENIX, INC. (SNGX) operates in the Pharmaceutical Preparations industry.
What exchange does SNGX trade on?
SOLIGENIX, INC. (SNGX) trades on the Nasdaq.
Where is SOLIGENIX, INC. incorporated?
SOLIGENIX, INC. is incorporated in DE.
When was SOLIGENIX, INC. (SNGX)'s most recent SEC filing?
SOLIGENIX, INC. (SNGX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is SNGX's market cap?
SOLIGENIX, INC. (SNGX) has a market capitalization of $6.38M as of 2026-06-30.
What is SNGX's EPS (earnings per share)?
SOLIGENIX, INC. (SNGX)'s trailing twelve month EPS is $-0.64 as of 2026-06-30.
What is SNGX's ROE (return on equity)?
SOLIGENIX, INC. (SNGX)'s trailing twelve month Return on Equity (ROE) is -241.65% as of 2026-06-30.
What is SNGX's ROA (return on assets)?
SOLIGENIX, INC. (SNGX)'s trailing twelve month Return on Assets (ROA) is -125.95% as of 2026-06-30.
What is SNGX's EV/EBITDA?
SOLIGENIX, INC. (SNGX)'s trailing twelve month EV/EBITDA is 0.31x as of 2026-06-30.